Lawsuits Filed Against BIDU, NNOX and ODT - Jakubowitz Law Pursues Shareholders Claims
Back to Newsroom
Mentioned in this Article

Lawsuits Filed Against BIDU, NNOX and ODT - Jakubowitz Law Pursues Shareholders Claims

Friday, September 18, 2020 2:55 PM
Share this article now
Topic:
Lawsuits

NEW YORK, NY / ACCESSWIRE / September 18, 2020 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.

Baidu, Inc. (NASDAQ:BIDU)

CONTACT JAKUBOWITZ ABOUT BIDU:
https://claimyourloss.com/securities/baidu-inc-loss-submission-form-2/?id=9401&from=1

Class Period: April 8, 2016 - August 13, 2020

Lead Plaintiff Deadline: October 19, 2020

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Baidu misrepresented the financial and business condition of iQIYI; (2) iQIYI had inadequate controls; and (3) as a result, Defendants' public statements were materially false and/or misleading at all relevant times.

Nano-X Imaging Ltd. (NASDAQ:NNOX)

CONTACT JAKUBOWITZ ABOUT NNOX:
https://claimyourloss.com/securities/nano-x-imaging-ltd-loss-submission-form/?id=9401&from=1

Class Period: August 21, 2020 - September 15, 2020

Lead Plaintiff Deadline: November 16, 2020

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Nano-X's commercial agreements and its customers were fabricated; (2) Nano-X's statements regarding its "novel" Nanox System were misleading as the Company never provided data comparing its images with images from competitors' machines; (3) Nano-X's submission to the U.S. Food and Drug Administration admitted the Nanox System was not original; and (4) as a result, Defendants' public statements were materially false and/or misleading at all relevant times.

Odonate Therapeutics, Inc. (NASDAQ:ODT)

CONTACT JAKUBOWITZ ABOUT ODT:
https://claimyourloss.com/securities/odonate-therapeutics-inc-loss-submission-form/?id=9401&from=1

Class Period: December 7, 2017 - April 21, 2020

Lead Plaintiff Deadline: November 16, 2020

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the Company's orally administered chemotherapy agent, tesetaxel, was not as safe or well-tolerated as the Company had led investors to believe; (ii) consequently, tesetaxel's commercial viability as a cancer treatment was overstated; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887

SOURCE: Jakubowitz Law

Jakubowitz Law
Back to Newsroom
Copyright 2020 © ACCESSWIRE. All rights reserved. Privacy Policy  |  Terms and Conditions
Drop us a line: